NYSE Biotech Firm Unveils Game-Changing Antiviral Candidate!

You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Small Caps Daily.

NYSE Biotech Firm Unveils Game-Changing Antiviral Candidate!

NanoViricides (NYSE: NNVC)’s broad-spectrum antiviral drug NV-387 is poised to cause a revolution in the treatment of viral diseases!

New viruses and existing viruses acquiring greater pathology and infectivity are bound to keep appearing in time. To combat such threats, we need to develop broad-spectrum drug arsenal that the viruses cannot escape. Vaccines and antibodies simply will not do, as their limitations have become clearly evident during the COVID-19 pandemic.

Rising biotech firm NanoViricides (NYSE: NNVC) may have a solution. It’s the company’s lead drug candidate NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections.

NV-387 has already been found to be able to cure lethally RSV infected mice and now the company is working towards a Phase II clinical trial to evaluate the effectiveness of NV-387 for the treatment of MPox patients.

NV-387 was found to possess strong antiviral activity against an orthopoxvirus in an animal model that is considered an important model to establish potential effectiveness against MPox and Smallpox viruses, as all of these viruses belong to the same family of orthopoxviruses.

There is currently no drug available for the treatment of hMPXV infection that causes MPox disease! A truly effective antiviral drug that works against MPox/Smallpox is needed by the government agencies and this could put NNVC on the map!

NV-387 may also be the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug! The company has recently engaged a Clinical Research Organization (CRO) to conduct Phase II clinical trial advancing its broad-spectrum antiviral drug NV-387 further into the regulatory pipeline.

Rising viruses are a cry out for the world to look for new approaches for pandemic preparedness and NNVC may have it.

See how NNVC’s treatment solves the greatest problem in antiviral countermeasures and could lead to exponential growth for the company!

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security.

We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of NanoViricides, Inc. (NYSE American: NNVC). The compensation consists of up to $3,500 and was received/will be received from Interactive Offers.

This compensation should not be considered as an endorsement of the securities of adviser NanoViricides, Inc. (NYSE American: NNVC) and we are not responsible for any errors or omissions in any information provided about the securities of NanoViricides, Inc. (NYSE American: NNVC) and Interactive Offers.

We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions.

This disclosure is made as of 02/24/2025.

Behind the Markets

Copyright © 2024 Behind the Markets, LLC, All rights reserved.
You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices.

You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here.

Today's Bonus Content: Buy These 7 Stocks for CHEAP

(By clicking this link you agree to receive emails from Trading Tips and our affiliates. You can opt out at any time.)